z-logo
open-access-imgOpen Access
Interleukin-13 −1112 C/T Promoter Polymorphism Confers Risk for COPD: A Meta-Analysis
Author(s) -
Lei Chen,
Yongchun Shen,
Lian Liu,
Xiaoou Li,
Tao Wang,
Fuqiang Wen
Publication year - 2013
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0068222
Subject(s) - copd , meta analysis , odds ratio , genotype , medicine , confidence interval , gastroenterology , subgroup analysis , genetic model , case control study , polymorphism (computer science) , pulmonary disease , publication bias , immunology , biology , genetics , gene
Background Interleukin (IL)-13, a T-helper type 2 cytokine, plays a critical role in the development of chronic obstructive pulmonary disease (COPD). This meta-analysis was performed to assess the association of IL-13 −1112 C/T promoter polymorphism with COPD susceptibility. Methods Published case-control studies from Pubmed and China National Knowledge Infrastructure (CNKI) databases were retrieved. Data were extracted and pooled odds ratios (OR) with 95% confidence intervals (CI) were calculated. Results Eight case-control studies in seven articles were included in this meta-analysis. Pooled effect size showed IL-13 −1112 C/T was associated with COPD susceptibility in a codominant genetic model (TT vs CT, OR: 1.82, 95% CI: 1.14–2.92 and TT vs CC, OR: 2.02, 95% CI: 1.10–3.72), indicating individuals with TT genotype had an increased risk for COPD compared with those with CT or CC genotype. According to ethnicity, results indicated IL-13 −1112 C/T was correlated with COPD susceptibility in Arabians (TT vs CT, OR: 2.94, 95% CI: 1.03–8.42 and TT vs CC, OR: 3.05, 95% CI: 1.08–8.59). Moreover, after excluding the study without Hardy-Weinberg equilibrium, the pooled results were robust and no publication bias was found in this study. Conclusions This meta-analysis suggests IL-13 −1112 C/T promoter polymorphism is associated with the risk of COPD in Arabians.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here